Senzime AB (publ) logo

SEZI - Senzime AB (publ) Share Price

SEK23.2 -1.3  -5.3%

Last Trade - 29/09/20

Sector
Healthcare
Size
Small Cap
Market Cap £121.2m
Enterprise Value £114.0m
Revenue £764k
Position in Universe 743rd / 1785
Bullish
Bearish
Unlock SEZI Revenue
Momentum
Relative Strength (%)
1m +2.45%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -14.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
502.4
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.54 0.15 1.63 0.19 3.21 6.71 36.0 68.0 +65.5%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Senzime AB (publ) revenues increased from SEK1.6M to SEK3.7M. Net loss increased 24% to SEK21.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Personnel Expenses increase of 77% to SEK10.3M (expense), Selling and Administrative Expenses increase of 8% to SEK7.1M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

SEZI Revenue Unlock SEZI Revenue

Net Income

SEZI Net Income Unlock SEZI Revenue

Normalised EPS

SEZI Normalised EPS Unlock SEZI Revenue

PE Ratio Range

SEZI PE Ratio Range Unlock SEZI Revenue

Dividend Yield Range

SEZI Dividend Yield Range Unlock SEZI Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
SEZI EPS Forecasts Unlock SEZI Revenue
Profile Summary

Senzime publ AB is a Sweden-based company engaged in the development, manufacture and marketing of biosensors for measuring metabolites in biological fluids, such as human blood and cell culture substrates for the pharmaceutical and healthcare segments. The Company focuses on the following application areas: medical diagnostic instruments, pharmaceutical industry, chemical processing, and food and beverage processing. As of December 31, 2011, the Company marketed three products, namely SENZ-100G, for continuous analysis of glucose in the fermentation solutions; SENZ-100L, for continuous analysis of lactate in fermentation solutions, and SENZ-200G, for continuous analysis of glucose in blood during intensive care.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Public Since June 18, 2008
No. of Shareholders: n/a
No. of Employees: 12
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index
Exchange OMX Nordic Exchange Stockholm
Shares in Issue 57,348,290
Free Float (0.0%)
Eligible for
ISAs
SIPPs
SEZI Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for SEZI
Upcoming Events for SEZI
Frequently Asked Questions for Senzime AB (publ)
What is the Senzime AB (publ) share price?

As of 29/09/20, shares in Senzime AB (publ) are trading at SEK23.2, giving the company a market capitalisation of £121.2m. This share price information is delayed by 15 minutes.

How has the Senzime AB (publ) share price performed this year?

Shares in Senzime AB (publ) are currently trading at SEK23.2 and the price has moved by 95.22% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Senzime AB (publ) price has moved by 0.119k% over the past year.

What are the analyst and broker recommendations for Senzime AB (publ)?

Of the analysts with advisory recommendations for Senzime AB (publ), there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Senzime AB (publ) is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Senzime AB (publ) next release its financial results?

Senzime AB (publ) is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Senzime AB (publ) dividend yield?

Senzime AB (publ) does not currently pay a dividend.

Does Senzime AB (publ) pay a dividend?

Senzime AB (publ) does not currently pay a dividend.

When does Senzime AB (publ) next pay dividends?

Senzime AB (publ) does not currently pay a dividend.

How do I buy Senzime AB (publ) shares?

To buy shares in Senzime AB (publ) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Senzime AB (publ)?

Shares in Senzime AB (publ) are currently trading at SEK23.2, giving the company a market capitalisation of £121.2m.

Where are Senzime AB (publ) shares listed? Where are Senzime AB (publ) shares listed?

Here are the trading details for Senzime AB (publ):

Country of listing: Sweden
Exchange: STO
Ticker Symbol: SEZI
What kind of share is Senzime AB (publ)?

Based on an overall assessment of its quality, value and momentum, Senzime AB (publ) is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Senzime AB (publ) share price forecast 2020?

Shares in Senzime AB (publ) are currently priced at SEK23.2. At that level they are trading at 14.29% premium to the analyst consensus target price of 0.00.

Analysts covering Senzime AB (publ) currently have a consensus Earnings Per Share (EPS) forecast of -0.4 for the next financial year.

How can I tell whether the Senzime AB (publ) share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Senzime AB (publ). Over the past six months, the relative strength of its shares against the market has been 36.62%. At the current price of SEK23.2, shares in Senzime AB (publ) are trading at 33.45% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Senzime AB (publ) PE Ratio?

We were not able to find PE ratio data for Senzime AB (publ).

Who are the key directors of Senzime AB (publ)?

Senzime AB (publ)'s management team is headed by:

Adam Dahlberg - DRC
Philip Siberg - CHM
Anders Jacobson - CTO
Sorin Brull - DRC
Catrin Molund - VBD
Pernilla Abrahamsson - OTH
David Hampton - CSO
Rianne Lundqvist Waninge - OTH
Lennart Kalen - DRC
Pia Renaudin - CEO
Anders Selin - VPR
Erik Bergman - CFO
Chris Estes - GMG
Who are the major shareholders of Senzime AB (publ)?

Here are the top five shareholders of Senzime AB (publ) based on the size of their shareholding:

Handelsbanken Asset Management Investment Advisor/Hedge Fund
Percentage owned: 6.3% (3.61m shares)
Handelsbanken MicroCap Sverige Mutual Fund
Percentage owned: 5.41% (3.10m shares)
Alfred Berg Kapitalförvaltning AB Investment Advisor/Hedge Fund
Percentage owned: 4.28% (2.45m shares)
Lansforsakringar Smabolag Sverige Mutual Fund
Percentage owned: 4.28% (2.45m shares)
Swedbank Robur Fonder AB Investment Advisor/Hedge Fund
Percentage owned: 3.28% (1.88m shares)
Similar to SEZI
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.